Loading...
•
Sep 30, 2020
Amedisys Q3 2020 Earnings Report
Amedisys reported strong Q3 2020 financial results, exceeding internal and external expectations and leading to increased full-year guidance.
Key Takeaways
Amedisys reported a net service revenue increase of $49.5 million to $544.1 million compared to 2019, and a net income attributable to Amedisys, Inc. of $72.0 million compared to $34.1 million in 2019. Adjusted net income attributable to Amedisys, Inc. was $74.6 million compared to $37.9 million in 2019. The company is integrating Aseracare and has paid down a portion of its debt.
Net service revenue increased to $544.1 million compared to $494.6 million in 2019.
Net income attributable to Amedisys, Inc. reached $72.0 million compared to $34.1 million in 2019.
Adjusted EBITDA was $75.7 million compared to $56.8 million in 2019.
Full year 2020 guidance ranges were increased.
Amedisys
Amedisys
Forward Guidance
Amedisys anticipates net service revenue to be in the range of $2.067 billion to $2.072 billion, adjusted EBITDA to be in the range of $269 million to $272 million, and adjusted diluted earnings per share to be in the range of $6.02 to $6.08.
Positive Outlook
- Net service revenue is anticipated to be in the range of $2.067 billion to $2.072 billion.
- Adjusted EBITDA is anticipated to be in the range of $269 million to $272 million.
- Adjusted diluted earnings per share is anticipated to be in the range of $6.02 to $6.08.
- Guidance excludes the effects of any future acquisitions.
- Based on an estimated 33.4 million shares outstanding.
Challenges Ahead
- Home health, hospice and personal care industries are highly competitive.
- The industries are subject to intensive regulations.
- Trends are subject to numerous factors, risks, and uncertainties.
- Changes in existing federal and state laws or regulations.
- Changes in Medicare and other medical payment levels.